latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/johnson-johnson-s-tremfya-tops-novartis-cosentyx-in-psoriasis-trial-48904561 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Johnson & Johnson's Tremfya tops Novartis' Cosentyx in psoriasis trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Johnson & Johnson's Tremfya tops Novartis' Cosentyx in psoriasis trial

Johnson & Johnson's plaque psoriasis drug Tremfya was more successful than Novartis AG's Cosentyx in treating the disease in a head-to-head late-stage trial.

In Johnson & Johnson's phase 3 trial, called Eclipse, 84.5% of patients on Tremfya had a 90% improvement in psoriasis in 48 weeks, the company announced at the Inflammatory Skin Disease Summit in Vienna, Austria. With Novartis' Cosentyx, the improvement percentage was 70%. The drugs are both human monoclonal antibodies that block a protein to mute the immune system.

Novartis' head of global development, Eric Hughes, said the results do not take away from Cosentyx, as the medicine acted more quickly with patients achieving the baseline 90% psoriasis improvement at 12 weeks.

"The clinical relevance of this one time point that they presented is important and it needs to be seen," Hughes told S&P Global Market Intelligence in a Dec. 12 interview. "But we're really happy with the complete response that we've demonstrated in the variety of manifestations for psoriatic disease."

Cosentyx is in trials for two more indications, hidradenitis suppurativa and non-radiographic axial spondyloarthritis, both related autoimmune diseases.

"Our goal now is to expand and build upon the label we've already created," Hughes said.

Meanwhile, Johnson & Johnson is touting the long-term results of Trenfya.

"To make the best recommendations for their patients from among these options, physicians need long-term comparative safety and efficacy data," said Newman Yeilding, Johnson & Johnson's head of immunology development.